Powered by Blogger.
facebook twitter Youtube

Ripples Advisory News Update's

If you are looking Stock Cash Tips services for Indian Stock Market, then you are at a right place. Our Company experts continuously monitor Indian Share market and fully optimize Share market result for better. Get all the Share market tips solutions with us. Our mission is to help you succeed because we believe in you, your Ideas, and your dreams.

The L&T purchased 8,86,438 shares via open market on May 16 at Rs 979.81 per share, crossing the necessary 25 percent level to trigger the open offer on May 9.

Share price of Mindtree gained in the early trade on Friday after infrastructure and engineering major Larsen and Toubro (L&T) has increased its stake in the company to more than 26 percent.


The stake of L&T in Mindtree has risen to 26.48 percent after an open market purchase on May 16.

The L&T purchased 8,86,438 shares via open market on May 16 at Rs 979.81 per share, crossing the necessary 25 percent level to trigger the open offer on May 9.

Also Read - L&T now owns over 26% stake in Mindtree

However, pending approval of the Securities and Exchange Board of India (SEBI), L&T had to postpone the open offer scheduled on May 14. According to sources, the nod from SEBI is expected within a fortnight.

Once the approval is in place, L&T’s open offer for Mindtree shares can start.

L&T on May 9 upped its stake to 25.93 percent in Mindtree. A stake of over 25 percent stake in Mindtree means that L&T can call for board meetings and seek a seat on the Mindtree board. Sources said L&T had raised concerns about Mindtree’s governance and board practices and these matters would be the focus for L&T management.

At 09:38 hrs Mindtree was quoting at Rs 986.85, up to Rs 6.60, or 0.67 percent and Larsen & Toubro were quoting at Rs 1,337.50, up to Rs 0.60, or 0.04 percent on the BSE.

Get Stock Market Tips and MCX Tips for a free trial
Share
Tweet
Pin
Share
No comments
Higher VIX suggests that volatile swings could continue in the market ahead of the election outcome.

A terrific Thursday was in store for investors as bulls took control of D-Street from the word go on May 16 thanks to stable cues. The index recovered most of the losses in the previous trading session.


Bulls pushed the index back above 11,250 which is the 100-day exponential moving average (EMA), which is a positive sign.

For the bulls to completely take charge, the index has to close above 11,300 convincingly, suggest experts.

Among sectors the S&P BSE Oil & Gas rose 1.5 percent, followed by the S&P BSE realty that gained 1.3 percent, and the S&P BSE Power that was up 1.3 percent.

Volatility cooled down slightly but it is still near 4-year high. India VIX fell down 1.01 percent at 28.37. However higher VIX suggests that volatile swings could continue in the market ahead of the election outcome.

It is the third straight session of gain for Rupee. The rupee surged by 31 paise to close at 70.03 against the US dollar on Thursday amid a sharp rebound in the domestic equity markets, even as oil prices firmed up.

On the institutional front, FPIs were net sellers in Indian markets for Rs 953 crore while the DIIs were net buyers to the tune of Rs 948 cr, provisional data showed.

Big News: As many as 84 companies will declare their results for the quarter ended March later today which include names like Arvind, Bajaj Auto, Balkrishna Industries, CESC, Corporation Bank, City Union Bank, EIL, IOC, Dr. Lal Pathlabs, Sobha Ltd, UPL, and ZEE Learn Ltd.

Bajaj Auto: PAT likely to fall by 6% YoY to Rs 998 crore

EIL: PAT likely to grow by 35% to Rs 122 crore

IOC: PAT likely to fall by 28% YoY to Rs 3734 crore

(All estimates are from Motilal Oswal)

Technical View: Nifty forms a bullish candle on daily charts

Bulls pushed the index back above 11,250 which is the 100-day exponential moving average (EMA), which is a positive sign.

Nifty respected 100-day moving average placed at 11,138 for the fourth consecutive day in a row to reclaim 100-day and 5-day EMA.

However, for the bulls to completely take charge, the index has to close above 11,300 convincingly, suggest experts.

Three levels: 11100, 11300, 11500

Max Call OI: 12000, 12500

Max Put OI: 11000, 11500

Stocks in news: Bajaj Finserv March quarter Profit after tax (PAT) increased by 57 percent YoY basis to Rs 1,176, compared to Rs 748 crore seen in the year-ago period.

Technology firm KPIT has posted a consolidated net profit of Rs 30.9 crore and revenue from operations of Rs 501.2 crore for the quarter ended March 31.

The US Court of Appeals for the Federal Circuit ruled in favor of Dr. Reddy's and its co-defendants Mylan and Lupin in litigation related to patents of arthritis pain reliever drug Vimovo.

Life sciences provider TAKE Solutions May 16 recorded consolidated net profit at Rs 27.06 crore for the fourth quarter ending March 2019, compared to Rs 45.49 crore registered in the year ago.

Technical Recommendations: We spoke to ICICIdirect and here's what they have to recommend:

Tata Consultancy Services: Buy| LTP: Rs 2111| Target: Rs 2370| Stop Loss: Rs 1955| Upside 12% | Time Frame 6 months

State Bank of India: Buy| LTP: Rs 316| Target: Rs 351| Stop Loss: Rs 290|Upside – 11%| Time Frame 6 months

Disclaimer: The views and investment tips expressed by investment expert on Moneycontrol.com are his own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Get Stock Cash Tips to start from 2 Days Free Trial Click Here- Stock Market Tips “We Provide Secure, and Smooth Deals You Can Trust”
Share
Tweet
Pin
Share
No comments
Narnolia Financial Advisors expects the pharma company to report a net profit of Rs 545 crore as against Rs 500 crore in the last quarter

Dr. Reddy's Laboratories is slated to come out with its fourth-quarter earnings on May 17. Kotak Institutional Equities expects the pharma major to report a net profit of Rs 413.6 crore, up 36.9 percent year-on-year and down 14.8 percent quarter-on-quarter. Sales are expected to increase 7.7 percent YoY (down 1.1 percent QoQ) to Rs 3,807.5 crore.


Earnings before interest, tax, depreciation, and amortization (EBITDA) is likely to rise 42.6 percent YoY (down 3.7 percent QoQ) to Rs 785.5 crore.

The research firm expects the US business to grow $10 million QoQ, given the benefits of Propofol and Suboxone launches, but the same could be offset by continued erosion in Metoprolol sales. It forecasts 13 percent YoY growth for India and Russia/CIS 17 percent, with CIS benefiting from a favorable base effect as well. Rest of the World is expected to grow at 27 percent. Proprietary products, it said, will continue its sluggish trend, with only six percent QoQ growth off a low base.

Narnolia Financial Advisors expects the pharma company to report a net profit of Rs 545 crore as against Rs 500 crore in the last quarter. It expects revenue from the US business to increase nine percent QoQ to $243 million in Q4 FY19 on account of improvement in the base business and re-launch of the generic version of Suboxone in the US market.

It forecasts an improvement in Europe revenue on the back of improvement in supplies and new launches. Revenue from the emerging market will witness traction on healthy performance from Russia based on new launches, it said.

EBITDA margin may clock 23.4 percent growth on account of reduced R&D expenditure and other expenses in comparison to the previous year due to control on spends. The latter is on the back of cost optimization and productivity improvement initiatives, the report said.

For daily MCX tips and Stock Market calls click this link to get connected with us Stock Market Tips fill our Two Days Free Trial >>>
Share
Tweet
Pin
Share
No comments
Older Posts
  • 2 Days Free Trial
  • Commodity News
  • Home Ripples Advisory
  • Stock Cash Services

Stock Cash - Free Trial

Stock Cash - Free Trial

Follow Us

  • facebook
  • twitter
  • Google+
  • youtube

Recent posts

Categories

  • Stock Cash
  • Stock cash Tips
  • Stock cash Tips High accuracy

About me

About Me

Created with by ThemeXpose | Distributed by Blogger Templates